Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Mid Cap Fund median (34 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 06 Aug 2026 – 20 Aug 2026, limited by The Wealth Company Mid Cap Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | The Wealth Company Mid Cap Fund | Nifty Midcap 150 |
|---|---|---|
| 06 Aug 2026 | ₹100.00 | ₹100.00 |
| 07 Aug 2026 | ₹99.80 | ₹100.22 |
| 08 Aug 2026 | ₹99.80 | ₹100.22 |
| 10 Aug 2026 | ₹99.91 | ₹100.69 |
| 11 Aug 2026 | ₹99.88 | ₹100.64 |
| 12 Aug 2026 | ₹99.99 | ₹100.90 |
| 13 Aug 2026 | ₹99.94 | ₹100.98 |
| 14 Aug 2026 | ₹99.74 | ₹100.47 |
| 15 Aug 2026 | ₹99.74 | ₹100.47 |
| 17 Aug 2026 | ₹99.77 | ₹100.62 |
| 18 Aug 2026 | ₹99.39 | ₹100.23 |
| 19 Aug 2026 | ₹99.22 | ₹99.98 |
| 20 Aug 2026 | ₹99.92 | ₹100.34 |
| Metric | The Wealth Company · Regular NAV ₹9.98 Very High risk Unrated | Category median Mid Cap Fund · 34 funds |
|---|---|---|
| — | +8.71% | |
| — | +18.06% | |
| — | +16.16% | |
| — | +15.69% | |
| -0.08% | +16.93% | |
| +450.01% | — | |
| — | +19.07% | |
| — | +16.56% | |
| — | +16.43% | |
| Risk | ||
| — | 16.23% | |
| — | 0.74 | |
| — | 1.00 | |
| -0.78% | -37.39% | |
| Nifty Midcap 150 | — | |
| — | +0.94% | |
| — | 0.94 | |
| — | 96.2% | |
| — | 90.1% | |
| 2.47% | 2.04% | |
| — | ₹7,594Cr | |
| 1.00% | — | |
| None | — | |
| ₹250 | — | |
| ₹1.00K | — | |
| — | 41% | |
| Aparna Shanker · 0.1y | — | |
| 06 Aug 2026 | — | |
| — | — | |
| — | — | |
| — | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.